<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006591</url>
  </required_header>
  <id_info>
    <org_study_id>313A</org_study_id>
    <secondary_id>APV-430</secondary_id>
    <nct_id>NCT00006591</nct_id>
  </id_info>
  <brief_title>Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment</brief_title>
  <official_title>The Safety and Efficacy of a Ritonavir-Enhanced Agenerase Regimen as Salvage Therapy in HIV-Infected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gathe, Joseph, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if treatment with an anti-HIV drug containing
      ritonavir and Agenerase is safe and can lower the level of HIV in the blood in patients who
      have failed an anti-HIV drug treatment containing nelfinavir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-infected patients will be treated with a ritonavir-enhanced Agenerase regimen.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amprenavir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients may be eligible for this study if they:

          -  Are 18 years of age or older.

          -  Are HIV-positive.

          -  Have a viral load (level of HIV in the body) of more than 1,000 copies/ml.

          -  Have had more than 12 weeks of prior anti-HIV drug treatment.

          -  Have failed a previous anti-HIV treatment containing nelfinavir as the only protease
             inhibitor.

          -  Are responsive to Agenerase.

          -  Are able to follow study requirements.

        Exclusion Criteria

        Patients will not be eligible for this study if they:

          -  Are intolerant to ritonavir (an anti-HIV drug).

          -  Have or have had problems with absorption.

          -  Have liver disease or damage.

          -  Have pancreatic disease or damage.

          -  Have taken any protease inhibitor other than nelfinavir.

          -  Are receiving investigational drugs or devices from another study.

          -  Are pregnant or breast-feeding.

          -  Currently use triazolam, astemizole, ergot medications, cisapride, midazolam,
             bepridil, rifampin, terfenadine, or pimozide.

          -  Have a bleeding disorder.

          -  Have previously been treated with Agenerase.

          -  Are receiving nonnucleosides.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gathe, Joseph, M.D.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2004</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2000</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Ritonavir</keyword>
  <keyword>VX 478</keyword>
  <keyword>Salvage Therapy</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Drug Monitoring</keyword>
  <keyword>Nelfinavir</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Amprenavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

